What happened
On September 29, 2026, NRx Defense Systems, Inc., a subsidiary of NRx Pharmaceuticals, Inc. (NASDAQ: NRXP), entered a DARPA prime contract. The contract covers the SPARC-TMS clinical trial for treatment-resistant depression.
NRx said the contract is worth approximately $11.2 million, and DARPA initially obligated approximately $6.7 million. The performance period is 18 months. Payments depend on program milestones being met and accepted. The company said the trial has U.S. Food and Drug Administration approval and is expected to begin enrolling patients. The September 30, 2026 press release said SPARC-TMS is a single-day treatment protocol using robotic neuro-navigated transcranial magnetic stimulation with NRX-101.
Key numbers
| Metric | Latest | Change | Source |
|---|---|---|---|
| Initial contract award | $11.18 million | Press release | |
| Aggregate contract value | approximately $11.2 million | SEC 8-K | |
| Initially obligated by DARPA | approximately $6.7 million | SEC 8-K | |
| Performance period | 18 months | SEC 8-K |
Why it matters
This is a contract, not just a research update. It ties funding to a defined depression study and a named drug-device combination. OptimistFi's comparison shows the initial obligation is about 60% of the aggregate contract value, so a meaningful share still depends on future appropriations and DARPA options.
That matters for a company that depends on outside funding. The contract does not guarantee the full award. Either party can terminate it under certain circumstances, including if the program is judged unlikely to achieve its intended objectives. NRx Defense keeps ownership of inventions conceived or first actually reduced to practice under the contract, subject to government rights.
The filing also says the trial is designed to test a single-day treatment protocol using robotic neuro-navigated transcranial magnetic stimulation with NRX-101. That gives the filing a clearer clinical milestone than a generic collaboration or grant.
Browse: stock research on every company OptimistFi covers
What's next
NRx said the full contract terms will be filed as an exhibit to its Quarterly Report on Form 10-Q for the quarter ending September 30, 2026. The company said the FDA-approved SPARC-TMS trial is expected to begin enrolling patients. Enrollment progress and milestone acceptance would support the case, while delays or a termination notice would weaken it.
More from OptimistFi
- NRXP stock: the NRX Pharmaceuticals thesis, its status and the next test to watch
- United States Brent Oil Fund, LP (NYSE Arca: BNO) Tracks a Supply Gap
- Alpha Teknova, Inc. (NASDAQ: TKNO) Adds Regulatory Support for PluriFreeze
- Meta Platforms, Inc. (NASDAQ: META) Has a Conditional $18 Billion Bill
- Stock research on every company OptimistFi covers
- Latest stock research and investment-case updates
- OptimistFi: evidence-first equity research
Sources
- SEC 8-K — Reports the DARPA prime contract entered on September 29, 2026.
- Press release — Announces the $11,177,757.27 initial award on September 30, 2026.
Read the full OptimistFi thesis on NRX Pharmaceuticals, Inc.: https://optimistfi.com/stocks/NRXP
See what would break the NRX Pharmaceuticals, Inc. thesis and track it live on the OptimistFi Thesis-Break Engine.
Browse every company OptimistFi covers at optimistfi.com/stocks, or read the latest evidence-first research.
The full NRX Pharmaceuticals, Inc. investment case, its status and the next test to watch live on the NRX Pharmaceuticals, Inc. thesis page.
Originally published on OptimistFi, evidence-first equity research. More at optimistfi.com.
